AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sangamo Therapeutics Announces Participation at the Jefferies 2019 London Healthcare Conference

November 18, 2019 GMT

BRISBANE, Calif.--(BUSINESS WIRE)--Nov 18, 2019--

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21 at 4:40 p.m. GMT in London, UK.

The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. For more information about Sangamo, visit www.sangamo.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191118005718/en/

CONTACT: Investor Relations – Global

McDavid Stilwell

510-970-6000, x219

mstilwell@sangamo.comMedia Inquiries – Global

Aron Feingold

510-970-6000, x421

afeingold@sangamo.com

KEYWORD: CALIFORNIA EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: HEALTH STEM CELLS GENETICS RESEARCH SCIENCE BIOTECHNOLOGY

SOURCE: Sangamo Therapeutics, Inc.

Copyright Business Wire 2019.

PUB: 11/18/2019 04:05 PM/DISC: 11/18/2019 04:05 PM

http://www.businesswire.com/news/home/20191118005718/en